Celltrion
Celltrion Healthcare Co., Ltd., commonly known as Celltrion, is a leading biopharmaceutical company headquartered in South Korea (KR). Founded in 2002, Celltrion has established itself as a key player in the global biotechnology industry, focusing on the development, manufacturing, and marketing of biosimilars and innovative therapeutics. With a strong presence in major operational regions including Europe, the Americas, and Asia, Celltrion is renowned for its core products, such as Remsima and Truxima, which are biosimilars to established monoclonal antibodies. These products are distinguished by their high quality and affordability, making advanced treatments accessible to a broader patient population. Celltrion's commitment to research and development has led to significant milestones, including the successful launch of multiple biosimilars that have garnered regulatory approvals worldwide. As a pioneer in the biosimilar market, Celltrion continues to enhance its market position through innovation and strategic partnerships, contributing to the evolution of healthcare solutions globally.
DitchCarbon Score
How does Celltrion's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Celltrion's score of 61 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Celltrion's reported carbon emissions
In 2024, Celltrion reported total greenhouse gas (GHG) emissions of approximately 1,394,000,000 kg CO2e. This figure includes 66,171,000 kg CO2e from Scope 1 emissions, primarily from mobile combustion, and 259,000 kg CO2e from Scope 2 emissions related to purchased electricity. The company also disclosed significant Scope 3 emissions, totalling about 1,327,970,000 kg CO2e, with upstream transportation and distribution accounting for the majority at approximately 1,327,340,000 kg CO2e. In 2023, Celltrion's emissions were lower, with total GHG emissions of about 28,798,000 kg CO2e from Scope 1 (22,457,000 kg CO2e) and Scope 2 (42,260,000 kg CO2e), alongside Scope 3 emissions of approximately 28,798,000 kg CO2e. This indicates a focus on reducing emissions across all scopes. Celltrion has set ambitious climate commitments, aiming to reduce GHG emissions by 50% by 2030 compared to 2020 levels. Additionally, the company is working towards achieving carbon neutrality by 2050. Specifically, for its domestic operations, Celltrion plans to mitigate Scope 1 and 2 emissions by 42% by 2030 and achieve a 100% reduction by 2045, using 2022 as the baseline year. These commitments reflect Celltrion's proactive approach to addressing climate change and reducing its carbon footprint, aligning with industry standards and expectations for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 16,864,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 31,667,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000 |
| Scope 3 | - | - | - | - | 00,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Celltrion is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
